This could subsequently decrease TB‐related complications and death rates.[88] In line with this, experiments with mice deficient in MMP‐9 have indicated a reduction in macrophage attraction to the lungs and smaller granuloma formations.[89] Moreover, research by Sabir's team indicated that using Marimastat to inhibit MMPs led to a decline in both granuloma formation and bacterial presence during M.tb infection, reinforcing the potential of MMP‐focused strategies as supplementary treatments for TB.[90]. This evidence concerns the gene MMP9 and tuberculosis.